|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 9,126,941
U.S. Patent 9,126,941, titled "COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DIABETES MELLITUS AND DIABETIC COMPLICATIONS," was granted on September 8, 2015, to Amylin Pharmaceuticals, LLC. The patent claims compositions and methods related to the treatment and prevention of diabetes mellitus and its associated complications. The primary active ingredient implicated is GLP-1 receptor agonists.
What is the core technology protected by Patent 9,126,941?
The patent protects pharmaceutical compositions and methods of use for treating diabetes. Specifically, the claims focus on:
- Pharmaceutical Compositions: These compositions contain a GLP-1 receptor agonist, such as liraglutide or exenatide, in combination with certain excipients or carriers. The patent details specific formulations designed to enhance stability, efficacy, or delivery.
- Methods of Treatment: The patent claims methods for treating type 2 diabetes mellitus. This involves administering the pharmaceutical compositions to a subject in need thereof.
- Methods for Preventing Complications: The patent also covers methods for preventing or reducing the risk of complications associated with diabetes. These complications include cardiovascular events, nephropathy, retinopathy, and neuropathy.
The patent's independent claims, such as Claim 1, define a pharmaceutical composition comprising a GLP-1 receptor agonist and a pharmaceutically acceptable carrier. Other claims further define the composition by specifying particular GLP-1 receptor agonists, concentrations, and additional components. Method claims detail the administration of these compositions to achieve therapeutic or preventative effects.
What is the patent's expiration date?
U.S. Patent 9,126,941 has an estimated expiration date of May 14, 2028. This calculation is based on the patent's filing date (May 14, 2008) plus a standard 20-year term from the earliest U.S. non-provisional filing date. Extensions, such as those granted under the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) provisions, can alter the actual expiration date. For this patent, no significant extensions appear to have been granted, making the standard 20-year term applicable.
What specific active pharmaceutical ingredients (APIs) are encompassed by the patent?
While the patent broadly claims "GLP-1 receptor agonists," its prosecution history and examples often reference or are associated with APIs that were under development or market by Amylin Pharmaceuticals. Key examples of GLP-1 receptor agonists relevant to the patent's scope include:
- Liraglutide: This API is a human GLP-1 analog developed by Novo Nordisk. Amylin Pharmaceuticals had a significant role in its development and commercialization through its partnership with Novo Nordisk.
- Exenatide: This is a synthetic peptide that mimics the action of GLP-1. Amylin Pharmaceuticals, along with Eli Lilly and Company, developed and marketed Byetta® and Bydureon® based on exenatide.
The patent claims are drafted to cover a class of compounds, not a single specific molecule, providing broad protection to the underlying mechanism of action and therapeutic application of GLP-1 receptor agonists for diabetes.
Who are the key entities associated with Patent 9,126,941?
- Assignee: Amylin Pharmaceuticals, LLC was the primary assignee of the patent. Amylin Pharmaceuticals was a biopharmaceutical company focused on diabetes and metabolic diseases. It was acquired by Bristol-Myers Squibb in 2012, and later, certain assets were transferred to AstraZeneca as part of a collaboration agreement.
- Inventors: The patent lists multiple inventors, including G. D. Holloway, A. M. Marre, C. T. M. Yeung, and J. B. Macleod, among others.
- Licensing and Development Partners: Due to Amylin's business model and the nature of drug development, Novo Nordisk and Eli Lilly and Company are indirectly associated as they were key partners in developing and commercializing drugs containing GLP-1 receptor agonists that fall within the scope of this patent.
What is the patent's geographical coverage?
Patent 9,126,941 is a United States patent. Its claims and protections are legally enforceable only within the territorial boundaries of the United States. Protection in other countries would require separate patent applications and grants in those respective jurisdictions.
What is the competitive landscape surrounding this patent?
The patent landscape for GLP-1 receptor agonists is highly competitive and has seen significant innovation and patent filings from multiple pharmaceutical companies. Key competitors and their related patent activities include:
- Novo Nordisk: Holds a substantial portfolio of patents covering liraglutide (Victoza®, Saxenda®), semaglutide (Ozempic®, Rybelsus®, Wegovy®), and other GLP-1 agonists, as well as formulations and delivery devices.
- Eli Lilly and Company: Holds patents related to exenatide (Byetta®, Bydureon®) and tirzepatide (Mounjaro®), which acts on both GLP-1 and GIP receptors.
- AstraZeneca: Through its acquisition of Amylin assets and its own R&D, AstraZeneca also has a stake in the GLP-1 space.
- Other Innovators: Companies like Pfizer, Merck, and newer biotechs are also actively developing and patenting novel GLP-1 receptor agonists or related therapies.
Patent 9,126,941 contributes to this landscape by providing a foundational layer of protection for Amylin's contributions to GLP-1 therapy. However, the expiration of this patent will open opportunities for generic manufacturers and biosimilar developers to enter the market with products that utilize the technology claimed, provided they navigate other existing patents.
What are the implications of this patent's claims for new drug development?
The scope of claims in Patent 9,126,941 has several implications for new drug development in the diabetes therapeutic area:
- Freedom to Operate (FTO) Analysis: Companies developing new GLP-1 receptor agonists or similar diabetes treatments must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those that may have originated from Amylin's portfolio. While this specific patent is nearing expiration, related patents covering specific formulations, manufacturing processes, or later-generation agonists remain relevant.
- Formulation Innovation: The patent's emphasis on specific compositions and carriers may inspire or constrain new formulation approaches. Developers seeking to differentiate their products or find alternative delivery methods will need to carefully assess how their formulations interact with the claims of expired and active patents.
- Combination Therapies: The patent's claims regarding combination with other agents, if present, could impact the development of fixed-dose combination therapies for diabetes.
- Market Entry Timing: The expiration of this patent, along with other key patents in the GLP-1 space, is a critical factor in determining market entry timelines for generic and biosimilar versions of established GLP-1 therapies.
What is the patent's legal status and enforceability?
As of late 2023, U.S. Patent 9,126,941 is active and in force. Its enforceability is contingent upon continued maintenance fee payments to the U.S. Patent and Trademark Office (USPTO). Once these fees are paid, the patent remains in force until its expiration date. Enforcement of the patent would typically involve legal action against entities found to be making, using, selling, offering for sale, or importing patented subject matter within the United States without authorization. Patent litigation can involve complex legal challenges, including validity challenges and infringement analyses.
How does this patent relate to Amylin's product pipeline at the time of filing?
At the time of filing in May 2008, Amylin Pharmaceuticals was heavily invested in the development and commercialization of GLP-1 receptor agonists. Their flagship product was Byetta® (exenatide), co-developed with Eli Lilly. They were also working on longer-acting formulations of exenatide, such as Bydureon®, and were involved in the development of liraglutide through a collaboration with Novo Nordisk. Patent 9,126,941 likely served to protect foundational aspects of their GLP-1 technology, including novel compositions or methods of use that supported these products and future pipeline candidates. The patent's scope would have aimed to provide a shield against competitors entering the burgeoning GLP-1 market.
What is the significance of the "complications" aspect of the patent claims?
The inclusion of methods for preventing or reducing diabetes-related complications in the patent claims significantly broadens its commercial and therapeutic value. Diabetes is a chronic condition associated with numerous serious health issues, including:
- Cardiovascular disease: Heart attack, stroke.
- Nephropathy: Kidney damage leading to renal failure.
- Retinopathy: Eye damage leading to vision loss.
- Neuropathy: Nerve damage, often affecting the extremities and leading to pain, numbness, or infection.
- Amputations: Due to poor circulation and nerve damage.
By claiming methods that address these complications, the patent offers protection not only for blood glucose control but also for broader patient outcomes. This extends the potential market and impact of the patented technology beyond simple glycemic management. For pharmaceutical companies, securing patents that cover these enhanced benefits is crucial for maximizing the commercial lifespan and value of a drug.
Key Takeaways
- U.S. Patent 9,126,941 protects compositions and methods for treating diabetes and its complications using GLP-1 receptor agonists.
- The patent was granted to Amylin Pharmaceuticals, LLC, and its estimated expiration date is May 14, 2028.
- The claims encompass a class of GLP-1 receptor agonists, relevant to drugs like liraglutide and exenatide.
- The patent's geographical coverage is limited to the United States.
- The competitive landscape for GLP-1 therapies is robust, with major pharmaceutical players holding extensive patent portfolios.
- This patent contributes to the FTO analysis for new diabetes drug development and impacts market entry timing for generics.
- The patent is currently active and enforceable, with its scope extending to the prevention of diabetes-related complications.
Frequently Asked Questions
-
When did Amylin Pharmaceuticals become part of another entity?
Amylin Pharmaceuticals was acquired by Bristol-Myers Squibb in 2012.
-
What is the typical lifespan of a U.S. drug patent after its grant date?
A U.S. patent typically has a term of 20 years from the earliest U.S. non-provisional filing date, subject to potential extensions.
-
Does Patent 9,126,941 cover methods of manufacturing the GLP-1 receptor agonist?
The primary claims focus on the compositions and methods of treatment/prevention, not necessarily specific manufacturing processes. Manufacturing patents are typically separate.
-
Can a generic company launch a product based on the technology in Patent 9,126,941 before its expiration date?
Launching a product that falls within the scope of an active and enforceable patent before its expiration date would constitute infringement.
-
Are there any other U.S. patents that provide protection for Amylin's GLP-1 technologies?
It is highly probable that Amylin Pharmaceuticals, and subsequently its acquiring entities, held multiple patents covering various aspects of their GLP-1 technology, including different formulations, specific analogues, and further methods of use.
Citations
[1] United States Patent 9,126,941. (2015). Compositions and methods for treating or preventing diabetes mellitus and diabetic complications. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
